Sexually Transmitted Diseases:
Condom Use and Risk of Gonorrhea and Chlamydia: A Systematic Review of Design and Measurement Factors Assessed in Epidemiologic Studies
Warner, Lee PhD, MPH*†; Stone, Katherine M. MD‡; Macaluso, Maurizio MD, DrPH*; Buehler, James W. MD†; Austin, Harland D. DSc†
From the *National Center for Chronic Disease Prevention and Health Promotion, Division of Reproductive Health, Centers for Disease Control and Prevention, Atlanta, Georgia; †Department of Epidemiology, Rollins School of Public Health of Emory University, Atlanta, Georgia; ‡National Center for HIV, STD, and TB Prevention, Division of STD Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia
The authors thank Ward Cates, Thomas Peterman, Dan Newman, Markus Steiner, Kate Curtis, Eileen Dunne, and John McGowan for their thoughtful comments and review of the manuscript. The authors also thank Summer Martins for providing invaluable assistance with development of Figure 1.
An earlier version of this manuscript was presented at the 2004 National STD Prevention Conference, Philadelphia, PA, March 8–11 [P116].
The findings and conclusions in this article are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention.
Correspondence: Lee Warner, PhD, MPH, Centers for Disease Control and Prevention, National Center for Chronic Disease and Health Promotion, Division of Reproductive Health, 4770 Buford Highway, Mailstop K-34, Atlanta, GA 30341. E-mail: firstname.lastname@example.org.
Received for publication March 11, 2005, and accepted June 14, 2005.
Background: Studies of condom use to reduce risk of most sexually transmitted infection provide inconsistent results. This inconsistency is often attributed to methodologic limitations yet has not been assessed systematically.
Objectives: The objectives of this study were to review studies of condom use and risk of gonorrhea and chlamydia, and to evaluate the importance of 4 key design and measurement factors on condom effectiveness estimates.
Design: We reviewed studies published 1966–2004 to assess risk reduction for gonorrhea and/or chlamydia associated with male condom use.
Results: Of 45 studies identified, most found reduced risk of infection associated with condom use. All studies reviewed had methodologic limitations: only 28 (62%) distinguished consistent from inconsistent use; 2 (4%) reported on correct use or use problems; 13 (29%) distinguished incident from prevalent infection; and one (2%) included a population with documented exposure to infection. Eight of 10 studies with 2 or more of these attributes reported statistically significant protective effects for condom use versus 15 of 35 studies with zero or one attribute (80% vs. 43%, P = 0.04).
Conclusions: Condom use was associated with reduced risk of gonorrhea and chlamydia in men and women in most studies, despite methodologic limitations that likely underestimate condom effectiveness. Epidemiologic studies that better address these factors are needed to provide more accurate assessment of condom effectiveness.
APPROXIMATELY 19 MILLION CASES of sexually transmitted infection (STI) occur in the United States each year.1 For sexually active persons, male latex condoms are the most commonly used contraceptive method to prevent STIs.2 When properly used, latex condoms prevent contact with semen; genital lesions and infected skin on the penile head and shaft; and penile contact with vaginal, oral, and anal discharges. In vitro studies indicate that latex condoms provide an effective mechanical barrier to passage of infectious agents comparable in size to or smaller than STI pathogens.3–11
Epidemiologic studies show that condoms are highly effective against HIV transmission. Recent meta-analyses of studies of discordant couples indicate consistent condom use reduces HIV risk by at least 80% to 94%.12–14 In contrast, risk reduction associated with condom use has been weaker and less consistent in studies of other STIs.15–22 This inconsistency was highlighted in a 2001 report by the National Institutes of Health17 and has been used by some to question the role of condoms as an STI prevention strategy.23,24
Biologic differences among STIs may contribute to differences in the level of protection that condoms afford. For example, condoms should be more effective against infections that are transmitted primarily from penile fluids (e.g., gonorrhea, chlamydia, trichomoniasis, hepatitis B virus, and HIV) than those also transmitted through contact with skin or mucosal surfaces in areas that may not be covered or protected by the condom (e.g., genital herpes, HPV, syphilis, and chancroid).2,15
Condom effectiveness against different STIs also could vary because of differences in the risk of transmission per sexual contact.25–28 The probability of acquiring infection from a single sexual act depends both on the population prevalence of infection25,29 and infectivity of the STI. Although not well-determined for most STIs, estimates of transmission risk per unprotected sex act with an infected partner are approximately 0.001 for HIV,30,31 0.20 to 0.50 for gonorrhea,32,33 0.45 for chlamydia,34 and 0.70 for chancroid.35 If condoms are less than 100% effective or are not used properly, the cumulative risk of infection for both condom users and nonusers will increase more rapidly for relatively infectious STIs than for those less infectious.26,28,36 Consequently, studies comparing users and nonusers will demonstrate less protection for highly infectious STIs (such as gonorrhea) than for less infectious STIs (such as HIV) even when the number of exposures to an infected partner is identical. Differences in numbers of sex acts occurring with infected partners also could explain variations in condom effectiveness estimates across studies against a specific STI, particularly one with high infectivity (e.g., gonorrhea). Specifically, studies with short observation periods may provide higher effectiveness estimates for condom use (i.e., more suggestive of protection) than studies of longer duration, simply because the number of sex acts occurring with infected partners is lower. This lack of comparability can be minimized by converting the estimate from a proportion to a rate.14
Differences in how STI exposure, condom use, and infection are ascertained may further complicate comparisons of condom effectiveness estimates across studies.15,17–22,29,36–55 Except for human papillomavirus18,19,54 and HIV,12–14 there has been little systematic examination of these factors on condom effectiveness estimates for most STIs.
Although gonorrhea and chlamydia are transmitted almost exclusively through sexual contact and should be easily preventable with proper condom use, previous reviews suggest highly variable risk reduction from condoms against these 2 infections.16,17,21 In this review, we systematically evaluate critical elements of design and measurement in studies of condom use and risk of gonorrhea and chlamydia and assess whether variations in these elements explain differences observed in condom effectiveness estimates.
We searched MEDLINE and article bibliographies to identify English-language, peer-reviewed epidemiologic studies published from January 1966 to April 2005 that assessed the association between male condom use and risk of gonorrhea or chlamydia. Articles were identified using the medical subject heading terms “condoms,” “contraceptive devices, male,” “gonorrhea,” “chlamydia,” and “sexually transmitted diseases, bacterial.” To be eligible, studies had to assess condom use during penile–vaginal intercourse; assess Neisseria gonorrhoeae or Chlamydia trachomatis infection using culture, antigen detection, or polymerase chain reaction (PCR); have a control or comparison group that included condom nonusers; and report a qualitative or quantitative association for the effect of condom use or provide data from which this association could be calculated. Two authors (LW and KMS) reviewed each study to determine eligibility.
Studies were grouped by type of STI and sex of participants. For each, we examined the study design, population or setting, sample size, measure(s) of condom use, duration of recall or follow up, confounders examined in multivariable analyses, and measure(s) of association between condom use and risk of infection. We reported point estimates (odds ratios, risk ratios, or hazard ratios) and 95% confidence intervals from the original source whenever possible; in some situations, we calculated measures of effect and their precision from data presented in the original article. If measures of effect were reported (or calculable) for multiple measures of condom use (e.g., “always use vs. never use” and “sometimes use vs. never use”), we gave preference to comparisons incorporating the category with the highest degree of consistent use. When the highest degree of consistent use was contrasted with multiple levels of less frequent use, we presented multiple comparisons. For comparisons across studies, we presented both unadjusted and adjusted estimates whenever possible; however, only unadjusted estimates were available for many studies. We considered study findings to show statistically significant differences between condom users and nonusers if the 95% confidence interval for the effect measure excluded the null value. Because this review was intended to assess findings and examine methodologic limitations across studies, we followed recommendations of others56,57 to consider studies individually and not aggregate studies for metaanalysis.
We assessed 4 key design or measurement elements by determining whether each study:
1. Distinguished consistent from inconsistent condom use; combining consistent users with inconsistent users introduces one type of nondifferential misclassification that could underestimate condom effectiveness, particularly when examining STIs with high infectivity;
2. Measured correct use and/or condom use problems; combining correct with incorrect users could introduce bias resulting in underestimation of condom effectiveness similar to that produced by combining consistent and inconsistent users. We evaluated whether studies reported on problems with condom use resulting in STI risk, including breakage or slippage during intercourse or withdrawal, application of condoms after onset of genital contact, and removal of condoms before ejaculation;
3. Used a study design that distinguished incident (new) infection from prevalent (pre-existing) infection; unlike cohort studies that assess incident infection, cross-sectional and most case–control studies do not permit determination of whether persons became infected before or after initiating condom use. Misclassifying the temporal sequence between condom use and infection could underestimate the effectiveness of consistent condom use; and
4. Selected a study population with documented exposure to gonorrhea or chlamydia during the time period pertaining to condom use; condoms can prevent transmission of STI only among persons exposed to an infected partner. Differences in STI exposure between condom users and nonusers can confound associations between condom use and infection.47,48,58,59 If condom users are more likely to choose sex partners at relatively low STI risk, the protective effect of condom use could be overestimated.59 Conversely, if condom users are more likely to encounter infected partners, as suggested by studies of sexually transmitted disease (STD) clinic patients, 44,60–62 the protective effect could be underestimated.47,48
We also considered other potentially important design and measurement factors (e.g., validity of self-reported condom use, sensitivity and specificity of diagnostic tests); however, a preliminary review of articles revealed it was not feasible to examine these factors across studies because of inadequate data. We refer readers elsewhere for discussion of these topics.29,38,39,41,43,45,52,55,63,64
Associations Between Condom Use and Infection
Forty-five studies47,48,52,60,65–105 met all eligibility criteria: 10 evaluated gonorrhea only, 19 evaluated chlamydia only, and 16 evaluated both infections individually (12 studies) or as a combined outcome (4 studies). Study populations consisted of attendees at STD clinics (n = 20), family planning clinics (n = 3), teen clinics (n = 3), college health clinics (n = 2), and other medical clinics (n = 1), or multiple clinic types (n = 5); commercial sex workers (n = 6); military recruits (n = 2); vocational school students (n = 1); and community members (n = 2). Studies used cross-sectional (n = 27), cohort (n = 13), and case–control (n = 5) designs. These 45 studies yielded 87 individual point estimates of the association between condom use and risk of gonorrhea or chlamydia after stratification by STI and sex.
Condom use was associated with reduced risk for gonorrhea in most studies; however, point estimates for the magnitude of protective effect varied widely and were not always statistically significant (Table 1 Fig. 1A, B). Eight studies evaluated gonorrhea among males, 6 studies69,79,92,98,100,101 of which reported (or provided information to calculate) risk reduction associated with condom use ranging from approximately 30%100 to 100%.79 Three of the 6 studies found statistically significant protective effects for condoms,69,98,101 whereas 3 reported protective effects that were not statistically significant.79,92,100 The remaining 2 studies52,87 reported no statistically significant association between condom use and gonorrhea, but did not provide sufficient information to quantify the association.
Sixteen studies evaluated condom use and gonorrhea among females. Fourteen67,68,74,76,77,80,84,85,87,93,96,97,100,101 reported (or provided information to calculate) risk reduction associated with condom use. Of these, 11 reported condom use reduced gonorrhea risk by 13%67 to 100%.74 In 9 studies,68,74,76,80,84,85,96,97,100 the protective effect reported was statistically significant. Three other studies77,87,101 reported no effect101 or increased gonorrhea risk among condom users, ranging from 60%87 to 120%.77 The 2 remaining studies52,89 reported no significant association, but available information was insufficient to quantify this association.
One additional study73 that evaluated gonorrhea in both males and females but did not report results by sex found condom use reduced gonorrhea risk by approximately 30% but was not statistically significant.
Condom use was similarly associated with reduced risk for chlamydia in most studies; however, like gonorrhea, point estimates varied widely and were not always statistically significant (Table 1, Fig. 1C, D). Of 8 studies that evaluated condom use and chlamydia among males,52,88,91,94,98,99,101,105 all reported (or provided information to calculate) estimates of risk reduction associated with condom use. Seven studies52,91,94,98,99,101,105 reported a protective effect, ranging from approximately 15%105 to 100%52 risk reduction. Three of these 7 studies52,94,101 reported a statistically significant protective effect. The remaining study88 showed an increased risk of chlamydia among condom users that was not statistically significant.
Of 27 studies that evaluated chlamydia among females, 21 reported (or provided information to calculate) estimates of risk reduction associated with condom use.65,68,70–72,74,76–78,80,81,83,86,89,91,95–97,101,103,104 Eighteen studies65,68,70–72,74,76,78,80,81,86,89,95–97,101,103,104 showed a protective effect, ranging from approximately 10%70,96,97 to 90%65,74 risk reduction. One or more statistically significant protective effects for condom use were reported in 10 studies,65,68,72,74,76,78,81,95,101,104 whereas 8 reported no significant protective effect.70,71,80,82,86,96,97,103 The other 3 reported condom use was associated with nonsignificant increased risk of chlamydia.77,83,91 For the remaining 6 studies,52,75,89,93,94,102 information was insufficient to quantify the association between condom use and chlamydia, although this association was reported as not statistically significant.
One additional study60 that evaluated chlamydia in males and females but did not stratify results by sex found condom use was not associated with risk of infection.
Gonorrhea and Chlamydia (Combined).
Four studies47,48,66,90 reported associations for gonorrhea or chlamydia as a combined outcome. Three reported that condom use was associated with statistically significant reductions in risk,47,48,66 ranging from approximately 50%66 to 58%,47 whereas the other90 reported a nonsignificant increased risk.
Assessment of Key Design and Measurement Factors
Consistency of Use.
Twenty-eight (62%) studies47,48,52,60,65,66,68–70,72–76,78,82,84,89–91,93,94,97–99,101,102,105 clearly distinguished participants who reported using condoms consistently from those who did not (Table 1). These studies categorized the highest frequency of self-reported condom use with terms such as “always use,” “consistent use,” or “100% use.” The remaining 17 studies67,71,77,79–81,83,85–88,92,95,96,100,103,104 categorized the highest frequency of self-reported condom use using terms such as “always or almost always use,” “sometimes or always use,” “ever use,” “any use,” or “use at last sex,” indicating that consistent users were likely grouped with inconsistent users. The proportion of studies that found one or more statistically significant protective effects did not differ between studies that distinguished consistent users from inconsistent users and those that did not (64% vs. 47%, P >0.20).
Correctness of Use and Condom Use Problems.
Only 2 studies48,69 assessed whether incorrect use or use problems occurred among participants, although neither fully assessed use problems that may result in STI exposure. One cross-sectional study of male STD clinic patients in London69 found gonorrhea prevalence was 4 times lower among those who reported using condoms consistently throughout intercourse with no unprotected genital contact than among those who used condoms incorrectly, inconsistently, or not at all (3.8% vs. 15.9%). Similarly, a large cohort study48 of female STD clinic patients in Alabama found the incidence of gonorrhea and chlamydia was lower among patients who used condoms consistently without breakage or slippage compared with patients who used condoms consistently but experienced these problems or who used condoms inconsistently or not at all. In the remaining 43 studies, correct users were likely grouped with incorrect users during analysis. In one smaller study73 of STD clinic patients in California, researchers did reinterview 2 participants who acquired gonorrhea despite reporting always using condoms, finding that both had applied the condom after starting intercourse.
Choice of Study Design.
Thirteen studies (29%) used prospective48,52,68,72,73,76,79,83,85,87,89,103 or retrospective cohort60 designs to distinguish incident from prevalent infection and could establish whether condom users acquired gonorrhea or chlamydia before or after they reported initiating condom use. Eight of these studies48,52,60,68,72,73,76,89 also assessed whether condoms were used with every sex act to document that infection occurred after onset of consistent condom use. The proportion of studies that found one or more statistically significant protective effects for condom use did not differ statistically between those that assessed incident versus prevalent infection (46% vs. 59%, P >0.20).
Selection of a Population With Gonorrhea or Chlamydia Exposure.
Only one study47 identified a population of participants who had documented exposure to infected sex partners during the same time period for which information on condom use was ascertained. In a cross-sectional analysis of data from STD clinic patients participating in Project RESPECT,106 the protective effect for consistent condom use was stronger among participants with known exposure to gonorrhea or chlamydia (who were referred to the clinic because they had recent sexual contact with an infected person) than among participants with unknown exposure to these infections (58% vs. 18% risk reduction, respectively).
The remaining 44 studies did not identify a population with documented exposure to gonorrhea or chlamydia. Twenty-three studies (51%),48,60,66–68,72,77,78,84,85,87,89,91,94–102,104 did attempt to adjust condom effectiveness estimates for differences in STI risk during analysis by using surrogate markers for STI exposure (including number of sex partners, previous STI diagnosis, number of sex acts, type or perceived risk of partners, and treatment status of partners). The proportion of studies that found one or more statistically significant protective effects was statistically higher between those that adjusted for surrogate markers and those that did not (74% vs. 41%, P = 0.03).
None of the 45 studies fully addressed all 4 factors, one (2%) addressed 3 factors, 9 (20%) addressed 2 factors, 23 (51%) addressed one factor, and 12 (27%) addressed none of these 4 factors (Table 2). The proportion of studies that found one or more statistically significant protective effects for condom use was higher among the 10 studies that examined at least 2 factors than among the 35 studies that examined either zero or one factor (80% vs. 43%, respectively, P = 0.04).
Despite methodologic limitations that tend to underestimate condom effectiveness, most studies in this review found that condom use was associated with reduced risk of gonorrhea and chlamydia in men and women. The magnitude of risk reduction varied widely, however, and was lower than expected given the physical barrier properties of condoms and route of transmission for these infections. All 45 studies had one or more methodologic limitations. Only 28 studies clearly distinguished self-reported consistent from inconsistent use of condoms, 2 assessed whether any type of incorrect condom use or condom use problems occurred, 13 distinguished incident from prevalent infection, and only one included a study population with documented exposure to infection. These inadequacies generally result in underestimation of condom effectiveness.18,20,21,43,45,47,48,52,54,55,60,61
Our findings highlight the general methodologic weakness of studies assessing condom use and risk of gonorrhea and chlamydia compared with studies of HIV, as previously emphasized in a National Institutes of Health report on condom effectiveness17 and elsewhere.15,21,47,48 No studies included in our review assessed the effect of consistent condom use on risk of incident gonorrhea or chlamydia among persons with documented exposure to infection, whereas nearly all studies included in meta-analyses of condom use and risk of HIV12–14 addressed these elements.
Statistically significant protective effects for condom use were more likely to be observed for studies addressing 2 or more design or measurement attributes compared with studies with none or only one of these attributes. This finding is noteworthy because much of the inconsistency in estimates of condom effectiveness has been attributed to inadequacies and variations in study measures, methods, and design. Our review provides empiric support that studies with weak designs to assess condom effectiveness generally underestimate effectiveness, thus contributing to the variation in estimates reported in the literature. This finding is tempered, however, by our inability to directly assess how the magnitude of protective effect related to the presence or absence of specific attributes apart from study sample size or power to detect a statistically significant difference.
Individually, none of the attributes we examined was associated with the likelihood of detecting statistically significant protective effects for condom use across studies. This finding likely resulted from poor measurement of individual attributes, simultaneous confounding from other methodologic limitations, and inadequate statistical power to detect this difference. For example, although the majority of studies assessed consistent use, reports that condoms were used “consistently” may not indicate use during every act of intercourse58,101,107,108 Self-reports of condom use also may be inaccurate,17,21,29,38,43,45,51,52,55,109,110 with overreporting being of greater concern than underreporting because of social desirability, which could lead to underestimation of effectiveness.
Only 2 studies in our review provided any information on incorrect use and condom use problems. In these studies, failure to use condoms throughout genital contact69 and breakage and slippage48 were predictive of infection. Similar findings regarding condom problems and the occurrence of STI have been reported in other studies.111,115,118,119 The general lack of information on condom problems was disconcerting in this review, given the high infectivity of these infections and evidence that problems occur commonly. For example, a cross-sectional study49 of 98 university men found that condoms broke, slipped off, or were not used throughout intercourse during 13% of uses in the previous month. Subsequent studies also have suggested a high frequency of these condom use problems111–119.
Notably only one study47 assessed directly whether participants had documented exposure to gonorrhea or chlamydia, and thus whether condom users and nonusers had comparable risk of infection. That study demonstrated that failure to adjust for differences in STI risk between condom users and nonusers led to substantial underestimation of condom effectiveness. Another study48 that used design techniques to approximate STI exposure revealed similar findings. These studies demonstrate that, although rarely done, populations of persons with known exposure to gonorrhea or chlamydia can be identified. As important, they illustrate how the protective effect for consistent and correct use can be masked when the critical variable, the infection status of the sex partner, is unknown.
The majority of studies did attempt to assess exposure indirectly by using surrogate markers for STI exposure. We also found studies that adjusted for surrogate markers were more likely to detect statistically significant protective effects for condom use than those that did not. These surrogates, although frequently associated with the infection status of study participants, may still be unreliable markers of the partner’s infection status.37 For example, there is no risk associated with having multiple partners if none are infected yet significant risk with having a single partner who is. In one analysis of condom effectiveness estimates,47 adjusting for surrogate markers of infection reduced confounding negligibly compared with restricting analyses to persons with known STI exposure. Failure to assure that condom users and nonusers were similarly exposed to infected partners could lessen the general validity of estimates of condom effectiveness.17,45,47,48,58
The possibility of differential exposure to infected partners between condom users and nonusers remains a somewhat major limitation in studies of curable STI.8,17,37,42,47,48,114,117 Recent studies have documented that people use condoms more often with partners who are likely to be infected with STI and less often with partners at low risk.44,60–62 A retrospective cohort study60 of 3568 STD clinic patients in Denver found, for example, that consistent and inconsistent condom users were both significantly more likely than nonusers to report having multiple partners (30% and 39%, respectively, vs. 18%) or a new partner (48% and 48%, respectively, vs. 26%). A prospective cohort study62 of 869 female STD clinic patients in Alabama also found that condom use was 60% higher among those with new or casual partners than among those with regular partners. If condom users as a group are at higher risk for STI than nonusers, condom effectiveness could be underestimated.
Theoretical solutions to the methodologic problems of differential exposure to STI are straightforward but typically unethical in practice. A randomized study in which participants were assigned to use or not use condoms with their prospective sex partners would generally be considered unethical17 except under very limited conditions.120,121 Prospective cohort studies of persons in relationships with infected partners (i.e., discordant couples) also would reduce differences in exposure between condom users and nonusers. Although this design has been used to evaluate condom effectiveness against chronic, incurable STIs such as HIV12–14 and herpes simplex virus,122 it would be unethical for curable STIs such as gonorrhea and chlamydia because infected persons must be treated promptly.15,17,45,47
This review updates previous reviews of gonorrhea and chlamydia16 that were less systematic17 or less focused on these 2 infections.21 By examining 2 STIs with high biologic plausibility for condom effectiveness, we could better assess the effect of design and measurement factors on observed estimates. Our findings extend those reported from a workshop on condom effectiveness led by the National Institutes of Health17 by examining a substantially larger number of studies for gonorrhea and chlamydia and by systematically reviewing key design and measurement factors for each. Our findings generally support arguments that better designed studies may be more likely to document protective effects for condom use.
The limitations of our review generally reflect limitations among the available studies. For example, the time period for observation varied widely across studies (from 4 days to 1 year) and was unspecified in more than one third of studies, thereby complicating our ability to evaluate specific design and measurement factors. We also could not assess the relative importance of each of the 4 factors examined because so few studies examined more than one. We suspect, however, that knowledge of STI exposure likely is the single critical factor through which the importance of other factors is demonstrated. Although we limited our review to 4 factors that influence effectiveness, other limitations not examined (e.g., potential inaccuracy of self-reported condom use, imperfect performance of diagnostic tests)38,52,55,58,61 also may contribute to underestimates of condom effectiveness. Lastly, by focusing on only these 4 factors, our review likely missed other strengths of individual studies. For example, one highly recognized cohort study79 of gonorrhea transmission among sailors who had had intercourse with sex workers while on shore leave demonstrated strong protection for condoms yet did not report on consistent use, correct use, or exposure to infection. Those limitations may have minimally impacted observed effectiveness because of other strengths, notably the study’s short duration and recall for condom use and the fact that all sailors were exposed to the same group of sex workers (and presumably same risk of infection).
Conclusions and Recommendations for Future Research
Most studies showed that condom use was associated with reduced risk for gonorrhea and chlamydia among men and women. However, the exact magnitude of risk reduction is difficult to quantify because of limitations and variations in the methods and design of these studies. We focused on 4 design and measurement elements minimally necessary for obtaining meaningful estimates of condom effectiveness against gonorrhea and chlamydia: measurement of consistent use and correct use, and assessment of incident infection and exposure to infection. Few studies addressed 2 or more factors simultaneously and none addressed all 4.
Finally, this review highlights recent advancements in design and measurement as well as areas to be addressed by future evaluations of condom effectiveness, especially for STIs with high infectivity. The 2 largest issues remain how best to measure condom use and how best to identify study populations with documented exposure to infection. Investigators can assess consistency and correctness of use with a brief module of questions, provided that other critical issues (e.g., exposure to infection) are adequately addressed. Consistency of use should be assessed during a time period appropriate for the population and STI under study (e.g., last 3 or 6 months)29,38,109 that also coincides with the period in which STI status is examined.51 Consistent use should be defined as use during every act of intercourse.38 Correctness of use and use problems should be limited to condom behaviors that result in direct STI exposure risk.49 Additional research is needed to determine whether the most appropriate referent category for consistent and correct use is nonuse as opposed to inconsistent/nonuse or the number of unprotected sex acts. Investigators should continue efforts to document the validity of self-reported use, given direct observation of condom use is not feasible. Recent advances in data collection may facilitate accurate reporting of condom use by increasing participant willingness to report less socially desirable behaviors and by facilitating recall of condom use and sexual behavior.29,38,41 New biologic markers that detect the presence of semen or other male genital fluids in the vagina42,45,123,124 also hold promise for documenting use or nonuse of condoms.
Documentation of exposure to infection, absent from all but one study in this review, remains critical for improving the accuracy of condom effectiveness estimates. Condom use and STIs should be assessed during the same time period when STI exposure occurred. Previously suggested prospective cohort designs for assessing condom effectiveness against curable STI,38 which can detect incident infection and somewhat minimize differences in STI exposure, still cannot ensure adequate measurement of exposure during the relevant time period; even in this situation, participants may choose to use condoms based on their partner’s risk. Limiting the study population to persons exposed to infection ensures that participants are at risk for STI during the actual period of observation, regardless of condom use. Recent evaluations of condom use and risk of gonorrhea and chlamydia47,48 suggest that populations likely exposed to these infections during the period of condom use assessment can be identified efficiently and inexpensively without requiring prohibitively large sample sizes.
1. Weinstock H, Berman S, Cates W. Sexually transmitted diseases among American youth: Incidence and prevalence estimates, 2000. Perspect Sex Reprod Health 2004; 36:6–10.
2. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines 2002. MMWR Morb Mortal Wkly Rep 2002; 51(RR-6):1–78.
3. Carey RF, Herman WA, Retta SM, et al. Effectiveness of latex condoms as a barrier to human immunodeficiency virus-sized particles under conditions of simulated use. Sex Transm Dis 1992; 19:230–234.
4. Carey RF, Lytle CD, Cyr WH. Implications of laboratory tests of condom integrity. Sex Transm Dis 1999; 26:216–220.
5. Judson FN, Ehret JM, Bodin GF, et al. In vitro evaluations of condoms with and without nonoxynol 9 as physical and chemical barriers against Chlamydia trachomatis, herpes simplex virus type 2, and human immunodeficiency virus. Sex Transm Dis 1989; 16:51–56.
6. Katznelson S, Drew WL, Mintz L. Efficacy of the condom as a barrier to the transmission of cytomegalovirus. J Infect Dis 1984; 150:155–157.
7. Kish LS, McMahon JT, Bergfield WF, et al. An ancient method and a modern scourge: The condom as a barrier against herpes. J Am Acad Dermatol 1983; 9:769–770.
8. Lytle CD, Routson LB, Seaborn GB, et al. Lack of latex porosity: A review of virus barrier tests. J Rubb Res 1999; 2:29–39.
9. Lytle CD, Routson LB, Seaborn GB, et al. An in vitro evaluation of condoms as barriers to a small virus. Sex Transm Dis 1997; 24:161–164.
10. Minuk GY, Bohme CE, Bowen TJ, et al. Efficacy of commercial condoms in the prevention of hepatitis B virus infection. Gastroenterology 1987; 93:710–714.
11. Rietmeijer CA, Krebs JW, Feorina PM, et al. Condoms as physical and chemical barriers against human immunodeficiency virus. JAMA 1988; 259:1851–1853.
12. Pinkerton SD, Abramson PR. Effectiveness of condoms in preventing HIV transmission. Soc Sci Med 1997; 44:1303–1312.
13. Weller S, Davis K. Condom effectiveness in reducing heterosexual HIV transmission. Cochrane Database Syst Rev 2001; 3:CD003255.
14. Davis KR, Weller SC. The effectiveness of condoms in reducing heterosexual transmission of HIV. Fam Plann Perspect 1999; 31:272–279.
15. Stone KM, Timyan J, Thomas EL. Barrier methods for the prevention of sexually transmitted diseases. In: Holmes KK, et al., eds. Sexually Transmitted Diseases, 3rd ed. New York: McGraw- Hill, 1999:1307–1321.
16. d’oro LC, Parazzini F, Naldi L, et al. Barrier methods of contraception, spermicides, and sexually transmitted diseases: A review. Genitourin Med 1994; 70:410.
18. Manhart L, Koutsky L. Do condoms prevent genital HPV infection, external genital warts, or cervical neoplasia? A meta-analysis. Sex Transm Dis 2002; 29:726–735.
19. Dunne EF, Markowitz L, Stone KM. Condoms and human papillomavirus infection: Implications for future research [Abstract P390]. 20th International Papillomavirus Conference; Paris, France; October 4–9, 2002.
20. Warner DL, Hatcher RA, Steiner M. Condoms. In: Hatcher RA, Trussell J, Stewart FH, et al., eds. Contraceptive Technology, 18th rev ed. New York: Ardent Media, 2004.
21. Holmes KK, Levine R, Weaver M. Effectiveness of condom in preventing sexually transmitted infections. Bull World Health Organ 2004; 84:454–461.
22. Warner DL, Stone KM, Buehler JW. Using epidemiology to understand condom effectiveness for preventing gonorrhea, chlamydia, and pelvic inflammatory disease [P116]. 2004 National STD Prevention Conference; March 8–11, 2004; Philadelphia, PA.
23. Cates W Jr. The NIH condom report: The glass is 90% full. Fam Plann Perspect 2001; 33:231–233.
24. Boonstra H. Public health advocates say campaign to disparage condoms threatens STD prevention efforts. The Guttmacher Report on Public Policy 2003; 6:1–3.
25. Cates W Jr. Contraception, contraceptive technology, and STDs. In: Holmes KK, Sparling PF, Mardh P-A, eds. Sexually Transmitted Diseases, 3rd ed. New York: McGraw-Hill, 1998. Pp. 1067–1078.
26. Mann JR, Stine CC, Vessey J. The role of disease-specific infectivity and number of disease exposures on long-term effectiveness of the latex condom. Sex Transm Dis 2002; 29:344–349.
27. Fitch JT, Stine C, Hager D, et al. Condom effectiveness: Factors that influence risk reduction. Sex Transm Dis 2002:811–817.
28. Cates W Jr. The condom forgiveness factor: The positive spin. Sex Transm Dis 2002; 29:350–352.
29. Aral SO, Peterman TA. Measuring outcomes of behavioural interventions for STD/HIV prevention. Int J STD AIDS 1996; 7(suppl 2): 30–38.
30. Gray R, Mawer MJ, Brookmeyer R, et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1 discordant couples in Rakai, Uganda. Lancet 2001; 357:1149–1153.
31. Mastro T, de Vincenzi I. Probabilities of sexual HIV-1 transmission. AIDS 1996; 10(suppl A):S75–S82.
32. Holmes KK, Johnson DW, Trostle HJ. An estimate of the risk of men acquiring gonorrhea by sexual contact with infected females. Am J Epidemiol 1970; 91:170–174.
33. Platt R, Rice PA, McCormack WM. Risk of acquiring gonorrhea and prevalence of abnormal adnexal findings among women recently exposed to gonorrhea. JAMA 1983; 250:3205–3209.
34. Lycke E, Lowhagen GB, Hallhagen G, et al. The risk of transmission of genital Chlamydia trachomatis infection is less than that of genital Neisseria gonorrhoeae infection. Sex Transm Dis 1980; 7:6–10.
35. Plummer FA, D’Costa LJ, Nsanze H, et al. Epidemiology of chancroid and Haemophilus ducreyi in Nairobi, Kenya. Lancet 1983; 2:1293–1295.
36. Feldblum PJ, Morrison CS, Roddy RE, et al. The effectiveness of barrier methods of contraception in preventing the spread of HIV. AIDS 1995; 9(suppl A):S85–S93.
37. Aral SO, Peterman TA. A stratified approach to untangling the behavioral/biomedical outcomes conundrum. Sex Transm Dis 2002; 29:530–532.
38. Crosby R, DiClemente RJ, Holtgrave DR, Wingood GM. Design, measurement, and analytical considerations for testing hypotheses relative to condom effectiveness against non-viral STIs. Sex Transm Infect 2002; 78:228–231.
39. Fishbein M, Pequegnat W. Evaluating AIDS prevention interventions using behavioral and biological outcome measures. Sex Transm Dis 2000; 37:101–110.
40. Hearst N, Chen S. Condom promotion for AIDS prevention in the developing world: Is it working? Stud Fam Plann 2004; 35:39–47.
41. Macaluso M, Artz L, Kelaghan J, et al. Prospective study of barrier contraception for the prevention of sexually transmitted diseases. Sex Transm Dis 1999; 26:127–136.
42. Macaluso M, Lawson ML, Hortin G, et al. Efficacy of the female condom as a barrier to semen during intercourse. Am J Epidemiol 2003; 157:289–297.
43. Pequegnat W, Fishbein M, Celentano D, et al. NIMH/APPC workgroup on behavioral and biological outcomes in HIV/STD prevention studies. Sex Transm Dis 2000; 27:127–132.
44. Peterman TA, Lin LS, Newman DR, et al. Does measured behavior reflect STD risk? An analysis of data from a randomized controlled behavioral intervention study. Sex Transm Dis 2000; 27:446–451.
45. Steiner MJ, Feldblum PJ, Padian N. Invited commentary: Condom effectiveness—Will prostate specific antigen shed new light on this perplexing problem? Am J Epidemiol 2003; 157:298–300.
46. Turner CF, Miller HG. Zenilman’s anomaly reconsidered: Fallible reports, ceteris paribus, and other hypotheses. Sex Transm Dis 1997; 24:522–527.
47. Warner L, Newman DR, Austin HD, et al. Condom effectiveness for reducing transmission of gonorrhea and chlamydia; The importance of assessing partner infection status. Am J Epidemiol 2004; 159:242–251.
48. Warner L, Macaluso M, Austin HD, et al. Application of the case–crossover design to reduce unmeasured confounding in studies of condom effectiveness Am J Epidemiol 2005; 161:765–773.
49. Warner L, Clay-Warner J, Boles J, Williamson J. Assessing correct condom use: Implications for evaluating condom use effectiveness. Sex Transm Dis 1998; 25:273–277.
50. Warner DL, Hatcher RA. A meta-analysis of condom effectiveness in reducing sexually transmitted HIV. Soc Sci Med 1994; 38:1169–1170.
51. Weir SS, Feldblum PJ. Condom use to prevent incident STDs [Letter]. Sex Transm Dis 1996; 23:76–77.
52. Zenilman JM, Weisman CS, Rompalo AM, et al. Condom use to prevent incident STDs: The validity of self-reported condom use. Sex Transm Dis 1995; 22:15–21.
53. Zenilman JM, Weisman CS, Rompalo AM, et al. In response: Condom use to prevent incident STDs: The validity of self-reported condom use. Sex Transm Dis 1996; 23:79–82.
55. Devine OJ, Aral SO. The impact of inaccurate reporting of condom use and imperfect diagnosis of sexually transmitted disease infection in studies of condom effectiveness. Sex Transm Dis 2004; 31:588–595.
56. Egger M, Schneider M, Smith GD, Spurious precision? Meta-analysis of observational studies. BMJ 1998; 316:140–144.
57. Greenland S. Meta-analysis. In: Rothman KJ, Greenland, eds. Modern Epidemiology, 2nd ed. Philadelphia: Lippincott-Ravin Publishers, 1998.
58. Thomas JC, Stratton S. Sexual transmission. In: Thomas JC, Weber DJ, eds. Epidemiologic Methods for the Study of Infectious Diseases. New York: Oxford University Press, 2001:267–287.
59. Halloran ME, Longini IM Jr. Using validation sets for outcome and exposure to infection in vaccine field studies. Am J Epidemiol 2001; 154:391–398.
60. Rietmeijer CA, Bemmelen RV, Judson FN, et al. Incident and repeat infection rates of Chlamydia trachomatis among male and female patients in an STD clinic. Sex Transm Dis 2002; 29:65–72.
61. Shlay J, McClung MW, Patnaik JL, et al. Comparison of sexually transmitted disease prevalence by reported level of condom use among patients attending an urban sexually transmitted disease clinic. Sex Transm Dis 2004; 31:154–160.
62. Macaluso M, Demand MJ, Artz LM, Hook EW. Partner type and condom use. AIDS 2000; 14:537–546.
63. Schachter J, Chow JM. The fallibility of diagnostic tests for sexually transmitted disease: The impact on behavioral and epidemiologic studies. Sex Transm Dis 1995; 22:191–196.
64. Quinn TC, Gaydos C, Shepherd M, et al. Epidemiologic and microbiologic correlates of Chlamydia trachomatis infection in sexual partnerships. JAMA 1996; 276:1737–1742.
65. Agacfidan A, Chow JM, Pashazade H, et al. Screening of sex workers in Turkey for Chlamydia trachomatis. Sex Transm Dis 1997; 24:573–575.
66. Ahmed S, Lutalo T, Wawer M, et al. HIV incidence and sexually transmitted disease prevalence associated with condom use: A population study in Rakai, Uganda. AIDS 2001; 16:2171–2179.
67. Austin H, Louv WC, Alexander J. A case–control study of spermicides and gonorrhea. JAMA 1984; 251:2822–2824.
68. Baeten JM, Nyange PM, Richardson BA, et al. Hormonal contraception and risk of sexually transmitted disease acquisition: Results from a prospective study. Am J Obstet Gynecol 2001; 185:380–385.
69. Barlow D. The condom and gonorrhoea. Lancet 1977; 222:811– 812.
70. Beck-Segue CM, Farshy CE, Jackson TK, et al. Detection of Chlamydia trachomatis cervical infection by urine tests among adolescent clinics. J Adolesc Health 1998; 22:197–204.
71. Brito de Sa A, Gomes JP, Viegas S, et al. Genital infection by Chlamydia trachomatis in Lisbon: Prevalence and risk markers. Fam Pract 2002; 19:362–364.
72. Burstein GR, Gaydos CA, Diener-West M, et al. Incident Chlamydia trachomatis infections among inner-city adolescent females. JAMA 1998; 280:521–526.
73. Darrow W. Condom use and use-effectiveness in high-risk populations. Sex Transm Dis 1989; 16:157–160.
74. Evans BA, Kell PD, Bond RA, et al. Heterosexual relationships and condom use in the spread of sexually transmitted diseases to women. Genitourin Med 1995; 71:291–294.
75. Faundes A, Telles E, Cristofoletti ML, et al. The risk of inadvertent intrauterine device insertion in women carriers of endocervical Chlamydia trachomatis. Contraception 1998; 58:105–109.
76. Fennema JSA, van Ameijden EJC, Coutinho RA, van Den Hoek A. Clinical sexually transmitted diseases among human immunodeficiency virus-infected and noninfected drug-using prostitutes. Associated factors and interpretation of trends, 1986 to 1994. Sex Transm Dis 1997; 24:363–371.
77. Fonck K, Kidula N, Kirui P, et al. Pattern of sexually transmitted disease and risk factors among women attending an STD referral clinic in Nairobi, Kenya. Sex Transm Dis 2000; 27:417–423.
78. Gaydos CA, Howell RM, Pare B, et al. Chlamydia trachomatis infections in female military recruits. N Engl J Med 1998; 339:739–744.
79. Hooper RR, Reynolds GH, Jones OG, et al. Cohort study of venereal disease. I: The risk of gonorrhea transmission from infected women to men. Am J Epidemiol 1978; 108:136–144.
80. Joesoef MR, Linnan M, Barakbah Y, et al. Patterns of sexually transmitted diseases in female sex workers in Surabaya, Indonesia. Int J STD AIDS 1997; 8:576–580.
81. Keim J, Woodard P, Anderson MK. Screening for Chlamydia trachomatis in college women on routine gynecological exams. J Am Coll Health 1992; 41:17–23.
82. Kettle H, Cay S, Brown A, Glasier A. Screening for Chlamydia trachomatis infection is indicated for women under 30 using emergency contraception. Contraception 2002; 66:251–253.
83. Kissinger P, Clayton JL, O’Brien ME, et al. Older partners not associated with recurrence among female teenagers infected with Chlamydia trachomatis. Sex Transm Dis.2002:144–149.
84. Klausner JD, Aplasca M-R, Mesola VP, et al. Correlates of gonococcal infection and of antimicrobial-resistant Neisseria gonorrhoeae among female sex workers, Republic of the Phillipines, 1996–7. J Infect Dis 1999; 179:729–733.
85. Levine WC, Revollo R, Kaune V, et al. Decline in sexually transmitted disease prevalence in female Bolivian sex workers: Impact of an HIV prevention project. AIDS 1998; 12:1899–1906.
86. Malotte CK, Wiesmeier E, Gelineau KJ. Screening for chlamydial cervicitis in a sexually active university population. Am J Public Health 1990; 80:469–471.
87. Mehta SD, Erbelding EJ, Zenilman JM, Rompalo AM. Gonorrhea reinfection in heterosexual STD clinic attendees: Longitudinal analysis of risks for first reinfection. Sex Transm Infect 2003; 79:124–128.
88. Mitike G, Genetu A, Kassu A, et al. A community based study of urogenital Chlamydia trachomatis in males aged fifteen years and above, Dembia District, northwest Ethiopia. Ethiop Med J 2002; 40:251–257.
89. Oh MK, Cloud GA, Fleenor M, et al. Risk for gonococcal and chlamydial cervicitis in adolescent females: Incidence and recurrence in a prospective cohort study. J Adolesc Health 1996; 18:270–275.
90. Paris M, Gotuzzo E, Goyzueta G, et al. Prevalence of gonococcal and chlamydial infections in commercial sex workers in a Peruvian Amazon City. Sex Transm Dis 1999; 26:103–107.
91. Paz-Bailey G, Kilmarx PH, Supawitkul S, et al. Risk factors for sexually transmitted diseases in Northern Thai adolescents. Sex Trans Diseases 2003; 30:320–326.
92. Pemberton J, McCann JS, Mahony JDH, et al. Socio-medical characteristics of patients attending a VD clinic and the circumstances of infection. Br J Vener Dis 1972; 48:391–396.
93. Peters SE, Beck-Sague CM, Farshy CE, et al. Behaviors associated with Neisseria gonorrhoeae and Chlamydia trachomatis: Cervical infection among young women attending adolescent clinics. Clin Pediatr 2000; 39:173–177.
94. Radcliffe KW, Ahmad S, Gilleran G, et al. Demographic and behavioural profile of adults infected with chlamydia: A case–control study. Sex Transm Infect 2001; 77:265–270.
95. Ramstedt K, Forssman L, Giesecke J, Granath F. Risk factors for Chlamydia trachomatis in 6810 young women attending family planning clinics. Int J STD AIDS 1992; 3:117–122.
96. Rosenberg MJ, Davidson AJ, Chen J-H, et al. Barrier contraceptives and sexually transmitted diseases in women: A comparison of female-dependent methods and condoms. Am J Public Health 1992; 82:669–674.
97. Sanchez J, Gotuzzo E, Escamilla J, et al. Sexually transmitted infections in female sex workers: Reduced by condom use but not by a limited periodic examination program. Sex Transm Dis 1998; 25:82–89.
98. Schwartz MA, Lafferty WE, Hughes JP, et al. Risk factors for urethritis in heterosexual men: The role of fellatio and other sexual practices. Sex Transm Dis 1997; 24:449–455.
99. Skaza A, Grskovic B, Plestina S, et al. Prevalence of asymptomatic chlamydial urethritis in military recruits in the Celje region, Slovenia. Int J STD AIDS 2003; 14:765–769.
100. Upchurch DM, Brady WE, Reichart CA, et al. Behavioral contributions to acquisition of gonorrhea in patients attending an inner-city sexually transmitted disease clinic. J Infect Dis 1990; 161:938–941.
101. van Duynhoven YTHP, van de Laar MJW, Schop WA, et al. Different demographic and sexual correlates for chlamydial infection and gonorrhoea in Rotterdam. Int J Epidemiol 1997; 26:1373–1385.
102. Vuylsteke B, Vandenbruaene M, Vandenbulcke P, et al. Chlamydia trachomatis prevalence and sexual behaviour among female adolescents in Belgium. Sex Transm Infect 1999; 75:152–155.
103. Whittington WLH, Kent C, Kissinger P, et al. Determinants of persistent and recurrent Chlamydia trachomatis infection in young women. Sex Transm Dis 2001; 28:117–123.
104. Williams KM, Wingood GM, DiClemente RJ, et al. Prevalence and correlates of Chlamydia trachomatis among sexually active African-American adolescent females. Prev Med 2002; 35:593–600.
105. Zelin JM, Robinson AJ, Ridgway GL, et al. Chlamydial urethritis in heterosexual men attending a genitourinary medicine clinic: Prevalence, symptoms, condom usage and partner change. Int J STD AIDS 1995; 6:27–30.
106. Kamb ML, Fishbein M, Douglas JM, et al. Efficacy of risk-reduction counseling to prevent human immunodeficiency virus and sexual transmitted diseases. JAMA 1998; 280:1161–1167.
107. Cecil H, Zimet GD. Meanings assigned by undergraduates to frequency statements of condom use. Arch Sex Behav 1998; 27:493–505.
108. Ness RB, Randall H, Richter HE, et al. Condom use and the risk of recurrent pelvic inflammatory disease, chronic pelvic pain, or infertility following an episode of pelvic inflammatory disease. Am J Public Health 2004; 94:1327–1329.
109. Catania JA, Gibson DR, Chitwood DD, et al. Methodological problems in AIDS behavioral research: Influences on measurement error and participation bias in studies of sexual behavior. Psychol Bull 1990; 108:339–362.
110. Turner CF, Miller HG. Zenilman’s anomaly reconsidered: Fallible reports, ceteris paribus, and other hypotheses. Sex Transm Dis 1997; 24:522–527.
111. Calzavara L, Burchell AN, Remis RS, et al. Delayed application of condoms is a risk factor for human immunodeficiency virus infection among homosexual and bisexual men. Am J Epidemiol 2003; 157:210–217.
112. Crosby R, Sanders S, Yarber WL, et al. Condom-use errors and problems: A neglected aspect of studies assessing condom effectiveness. Am J Prev Med 2003; 24:367–370.
113. Crosby RA, Sanders SA, Yarber WL, et al. Condom use errors and problems among college men. Sex Transm Dis 2002; 29:552–557.
114. Fishbein M, Pequegnat W. Evaluating AIDS prevention interventions using behavioral and biological outcome measures. Sex Transm Dis 2000; 37:101–110.
115. Hopperus Buma AP, Veltink RL, van Ameijden EJ, et al. Sexual behaviour and sexually transmitted diseases in Dutch marines and naval personnel on a United Nations mission in Cambodia. Genitourin Med 1995; 71:172–175.
116. Mertz KJ, Finelli L, Levine WL, et al. Gonorrhea in male adolescents and young adults in Newark, New Jersey. Sex Transm Dis 2000; 27:201–207.
117. Macaluso M, Kelaghan J, Artz L, et al. Mechanical failure of the latex condom in a cohort of women at high STD risk. Sex Transm Dis 1999; 26:450–458.
118. Paz-Bailey G, Koumans EH, Sternberg M, et al. The effect of correct and consistent use on chlamydial and gonococcal infection among urban adolescents. Arch Pediatr Adolesc Med 2005; 159:536–542.
119. Shlay JC, McClung MW, Patnaik JL, et al. Comparison of sexually transmitted disease prevalence by reported condom use: Errors among consistent condom users seen at an urban sexually transmitted disease clinic. Sex Transm Dis 2004; 31:526–532.
120. Hogewoning CJ, Bleeker MC, van den Brule AJ, et al. Condom use promotes regression of cervical intraepithelial neoplasia and clearance of human papillomavirus: A randomized clinical trial. Int J Cancer 2003; 107:811–816.
121. Bleeker MC, Hogewoning CJ, Voorhorst FJ, et al. Condom use promotes regression of human papillomavirus-associated penile lesions in male sexual partners of women with cervical intraepithelial neoplasia. Int J Cancer 2003; 107:804–810.
122. Wald A, Langenberg AG, Link K, et al. Effect of condoms on reducing the transmission of herpes simplex virus type 2 from men to women. JAMA 2001; 285:3100–3106.
123. Walsh TL, Frezieres RG, Peacock K, et al. Use of prostate-specific antigen (PSA) to measure semen exposure resulting from male condom failures: Implications for contraceptive efficacy and the prevention of sexually transmitted disease. Contraception 2003; 67:139–150.
124. Zenilman JM, Yuenger J, Gala N, et al. Polymerase chain reaction detection of Y chromosome sequences in vaginal fluid: Preliminary studies of a potential biomarker for sexual behavior. Sex Transm Dis 2005; 32:90–94.
Figure. No caption available.
This article has been cited 36 time(s).
Sexually Transmitted InfectionsDo condoms cause rape and mayhem? The long-term effects of condoms in New South Wales' prisonsSexually Transmitted Infections
Sexual HealthPending research issues in male condom use promotionSexual Health
International Journal of Std & AIDSCondom use in the year following a sexually transmitted disease clinic visitInternational Journal of Std & AIDS
Studies in Family Planning
Ethics, ideology, and reproductive health policy in the United States
Studies in Family Planning, 38(4):
Sexually Transmitted InfectionsApplication of cumulative odds logistic model on risk factors analysis for sexually transmitted infections among female sex workers in Kaiyuan city, Yunnan province, ChinaSexually Transmitted Infections
Sexual HealthCondom failure among men receiving sexually transmissible infection clinic services, Cape Town, South AfricaSexual Health
Hot Topics in Infection and Immunity in Children IV
Gonococcal infections in newborns and in adolescents
Hot Topics in Infection and Immunity in Children IV, 609():
Sexual HealthRefining self-reported condom use among young men at risk of HIV acquisitionSexual Health
Ajar-African Journal of AIDS ResearchReadiness of youth in rural Ethiopia to seek health services for sexually transmitted infectionsAjar-African Journal of AIDS Research
American Journal of Public HealthSocial-Environmental Factors and Protective Sexual Behavior Among Sex Workers: The Encontros Intervention in BrazilAmerican Journal of Public Health
Sexually Transmitted InfectionsA comparison of four condom-use measures in predicting pregnancy, cervical STI and HIV incidence among Zimbabwean womenSexually Transmitted Infections
American Journal of EpidemiologyEfficacy of the male latex condom and of the female polyurethane condom as barriers to semen during intercourse: A randomized clinical trialAmerican Journal of Epidemiology
Sexual HealthCondoms for sexually transmissible infection prevention: politics versus scienceSexual Health
Annals of EpidemiologyWeighting condom use data to account for nonignorable cluster sizeAnnals of Epidemiology
American Journal of EpidemiologyProblems with condom use among patients attending sexually transmitted disease clinics: Prevalence, predictors, and relation to incident gonorrhea and chlamydiaAmerican Journal of Epidemiology
American Journal of Obstetrics and GynecologyWomen at risk for sexually transmitted diseases: correlates of intercourse without barrier contraceptionAmerican Journal of Obstetrics and Gynecology
Perspectives on Sexual and Reproductive HealthPredictors of STDs among Asian and Pacific Islander young adultsPerspectives on Sexual and Reproductive Health
Journal of Health Population and Nutrition
Condom-use Skills Checklist: A Proxy for Assessing Condom-use Knowledge and Skills When Direct Observation Is Not Possible
Journal of Health Population and Nutrition, 27(3):
New England Journal of Medicine
Condoms and sexually-transmitted infections
New England Journal of Medicine, 354():
Determinants of contraceptive choice among women with HIV
Archives of Pediatrics & Adolescent Medicine
Efficacy of Sexually Transmitted Disease/Human Immunodeficiency Virus Sexual Risk-Reduction Intervention for African American Adolescent Females Seeking Sexual Health Services A Randomized Controlled Trial
Archives of Pediatrics & Adolescent Medicine, 163():
Health Technology AssessmentDissemination and publication of research findings: an updated review of related biasesHealth Technology Assessment
Srpski Arhiv Za Celokupno LekarstvoKnowledge, Attitudes and Behaviour of Adolescents About Reproductive Health at Belgrade TerritorySrpski Arhiv Za Celokupno Lekarstvo
Jama-Journal of the American Medical Association
Estimation of HIV incidence in the United States
Jama-Journal of the American Medical Association, 300(5):
Tropical Medicine & International HealthRandomized controlled trial to investigate impact of site-based safer sex programmes in Kingston, Jamaica: trial design, methods and baseline findingsTropical Medicine & International Health
Health Technology AssessmentThe effectiveness and cost-effectiveness of behavioural interventions for the prevention of sexually transmitted infections in young people aged 13-19: a systematic review and economic evaluationHealth Technology Assessment
Human ReproductionProstate-specific antigen in vaginal fluid after exposure to known amounts of semen and after condom use: comparison of self-collected and nurse-collected samplesHuman Reproduction
Sexually Transmitted DiseasesChlamydia trachomatis Among Young Norwegian Men: Sexual Behavior and Genitourinary SymptomsSexually Transmitted Diseases
Sexually Transmitted DiseasesEpidemiology of Genital Chlamydia trachomatis Infection Among Young Women in Costa RicaSexually Transmitted Diseases
Sexually Transmitted DiseasesCombined Hormonal Contraception May Be Protective Against Neisseria gonorrhoeae InfectionSexually Transmitted Diseases
Sexually Transmitted DiseasesA Systematic Review of Epidemiologic Studies Assessing Condom Use and Risk of SyphilisSexually Transmitted Diseases
© Copyright 2006 American Sexually Transmitted Diseases Association